“
TL;DR
This retrospective cohort study compared outcomes in 35 patients with advanced esophageal cancer treated with taxane monotherapy (October 2016–November 2018) and 37 patients treated with nivolumab (March 2020–September 2021).
PLOS ONE · 14 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This retrospective cohort study compared outcomes in 35 patients with advanced esophageal cancer treated with taxane monotherapy (October 2016–November 2018) and 37 patients treated with nivolumab (March 2020–September 2021).
This retrospective cohort study compared outcomes in 35 patients with advanced esophageal cancer treated with taxane monotherapy (October 2016–November 2018) and 37 patients treated with nivolumab (March 2020–September 2021). The median overall survival was 9.1 months for the taxane cohort and 12.5 months for the nivolumab cohort. In the nivolumab cohort, patients with good nutritional status had significantly better median overall survival than those with poor nutritional status (18.1 vs. 4.3 months, p = 0.012 for Glasgow prognostic score). The prognosis of patients treated with taxane therapy was less affected by nutritional status. The study suggests pretreatment nutritional status is a key factor for successful outcomes with nivolumab. Limitations include the retrospective design, lack of PD-L1/CD8+ tumor analysis, and inability to conduct subgroup analysis on histological types due to small sample size.